News
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 61.607 no-par value bearer shares at an issue price of EUR 17,50 per share
Marinomed Biotech AG resolves capital increase by issuing 61.607 bearer shares at EUR 17,50 per share, excluding statutory subscription rights -
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Marinomed Biotech AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research initiates coverage on Marinomed Biotech AG with a Buy rating and EUR 50.00 price target. Details of the company's dual business model and lead candidate, Budesolv, are highlighted -
-
